

12th International Conference on Stroke, Neurology and Cerebrovascular Diseases

Neurological Disorders Volume: 09

August 18-19, 2021 | Webinar

Anti- β 2-Glycoprotein I Autoantibody Expression as a Potential Biomarker for Strokes in Patients with Anti-Phospholipid Syndrome

Husham Bayazed

Zakho University, Scientific Research Center, Kurdistan Region, Iraq

Anti-phospholipid syndrome (APS) is an autoimmune disease. Cerebral ischemia associated with APS occurs at a younger age than typical atherothrombotic cerebrovascular disease and is often recurrent. This study sought to determine the frequency rates of anti-cardiolipin (aCL) dependent on the presence of β 2-GPI, anti- β 2-glycoprotein I ($\alpha\beta$ 2-GPI), and anti-phosphatidyl serine (aPS) IgG autoantibodies among stroke patients. Stroke patients and control subjects recruited from Mosul, Erbil, and Dohuk provinces in Northern Iraq were evaluated. All cases were under 50 years-of-age and had no recognizable risk factors. Using ELISA, the results indicated that the frequency of $\alpha\beta$ 2-GPI was 14/50 (28%), aCL was 11/50 (22%), and aPS was 9/50 (18%) among stroke patients. In contrast, aCL was detected in 2/30 (6.7%) of control subjects; each of the other anti-phospholipid antibodies (APLA) was never observed. Of all the $\alpha\beta$ 2-GPI+ cases, the incidence of stroke patients having the combined profile of $\alpha\beta$ 2-GPI + aCL was 11/14 (78.6%) and of $\alpha\beta$ 2-GPI + aPS was 9/14 (64.3%). Only 2/14 (14.3%) of these $\alpha\beta$ 2-GPI+ patients also expressed aCL in the absence of aPS. In none of the APS/stroke patients were aCL or aPS expressed in the absence of the $\alpha\beta$ 2-GPI. Conversely, $\alpha\beta$ 2-GPI as a sole marker was seen in 3/14 (21.4%) of these patients (i.e., in absence of either other marker). It can be concluded from these studies that among the three major forms of APLA examined, the presence of $\alpha\beta$ 2-GPI IgG autoantibodies appeared to correlate best with stroke in patients who were concurrently suffering APS.

Biography

Prof Dr. Husham Bayazed has completed his PhD from University of Mosul, College of Medicine. He is now Consultant Immunologist at Scientific Research Center, University of Zakho / Kurdistan Region. He is specialist in clinical Immunology with interest in Neuro-immunology and has published more than 25 papers in reputed journals and has been serving as scientific reviewers of many local and international medical journals. In addition of being Fellowship of ISC, Infection, Cancer and Immunology Advisory Board Member (EUROMDnet) (Belgium), Membership of World Stroke Organization, Membership of Metabolomics (USA), and Membership of American Association of Science & Technology.

halsinde@yahoo.com